NEW YORK (GenomeWeb News) - Following its initial public offering and Euronext listing on June 27, OncoMethylome Sciences said on Friday that it has raised an additional €3.3 million through the exercise of over-allotment option by Fortis and ING, the joint lead managers in the offering.
OncoMethylome granted the option on up to 440,000 new shares, at the IPO price of €7.5 per share.
As a result, the company's proceeds from the IPO total €25.3 million.